• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Inventiva S.A.

    9/5/23 4:58:15 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13G 1 qia-sc13g_083023.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Inventiva S.A.

    (Name of Issuer)

     

    Ordinary shares, par value €0.01 per share

    (Title of Class of Securities)

     

    46124U107

    (CUSIP Number)

     

    August 30, 2023

    (Date of Event Which Requires Filing this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐  Rule 13d-1(b)

    ☒  Rule 13d-1(c)

    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

      

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     
     

     

    CUSIP No.

    46124U107

     

               
    1   NAMES OF REPORTING PERSONS
    Qatar Investment Authority
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)    ☐
        (b)    ☒  
         
    3   SEC USE ONLY
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
        Qatar
           
      5   SOLE VOTING POWER
    NUMBER OF     0
    SHARES      
    BENEFICIALLY 6   SHARED VOTING POWER
    OWNED BY     5,157,233
    EACH      
    REPORTING 7   SOLE DISPOSITIVE POWER
    PERSON     0
    WITH:      
      8   SHARED DISPOSITIVE POWER
          5,157,233
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
        5,157,233 (see Item 4 below)
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        ☐
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
        9.97% (1)
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        OO

     

      (1)  Based on (1) 42,134,169 Ordinary Shares (as defined below) outstanding as of December 31, 2022 as reported in the Issuer’s (as defined below) Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023, and (2) 9,618,638 Ordinary Shares issued on August 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on August 31, 2023.

     

     
     

     

    CUSIP No.

    46124U107

     

    Item 1(a). Name of Issuer:
       
      Inventiva S.A. (the “Issuer”)
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
     

    50 rue de Dijon

    21121 Daix

    France

       
    Item 2(a). Name of Person Filing:
       
      Qatar Investment Authority (the “Reporting Person”)
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
      Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, P.O. Box 23224, Qatar.
       
    Item 2(c). Citizenship:
       
      Qatar
       
    Item 2(d). Title of Class of Securities:
       
      Ordinary shares, €0.01 par value per share (“Ordinary Shares”)
       
    Item 2(e). CUSIP Number:
       
      46124U107
       
    Item 3. If this statement is filed pursuant to §§ 240.13d—1(b) or 240.13d—2(b) or (c), check whether the person filing is a:
       
      Not applicable.
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:  
           
        5,157,233  
           
      (b) Percent of class: 9.97%  
           
      (c) Number of shares as to which the person has:  
           
        (i) Sole power to vote or to direct the vote  
           
          0  
           
        (ii) Shared power to vote or to direct the vote  
           
          5,157,233  
     
     

     

    CUSIP No.

    46124U107

     

         
        (iii) Sole power to dispose or to direct the disposition of  
           
          0  
           
        (iv) Shared power to dispose or to direct the disposition of  
           
          5,157,233  

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      See Exhibit A.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     
     

     

    CUSIP No.

    46124U107

     

    SIGNATURE

     

         After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 5, 2023

     

      QATAR INVESTMENT AUTHORITY
       
       
      By:    /s/ Andrew Watkins  
        Name: Andrew Watkins**
        Title:    Associate General Counsel, Head of Compliance

     

    ** Evidence of authority to sign on behalf of Qatar Investment Authority is set forth in a Certificate of Incumbency dated February 2, 2022, and included as Exhibit B hereto.

     

     

     

     
     

     

    CUSIP No.

    46124U107

     

    INDEX TO EXHIBITS

     

    Exhibit No.   Description  
         
    A   Item 7 Information
    B   Certificate of Incumbency

     

     

     
     

     

    CUSIP No.

    46124U107

     

    EXHIBIT A

     

     

    The Schedule 13G to which this attachment is appended is filed by Qatar Investment Authority on behalf of itself and the following subsidiaries:

     

     

    Qatar Holding LLC

     

     

     

     

     
     

     

    CUSIP No.

    46124U107

     

    EXHIBIT B

     

    CERTIFICATE OF INCUMBENCY

     

    I, Ahmad Mohammed F Q Al-Khanji, Chief of Legal and General Counsel, of Qatar Investment Authority, established by Emiri Decision No 22 in 2005, with its registered office at, Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State of Qatar, do hereby confirm that Andrew Watkins is the duly appointed Associate General Counsel, Head of Compliance, an officer of the Qatar Investment Authority, and as such, is authorized to sign regulatory filings on behalf of the Qatar Investment Authority.

     

       
      By:    /s/ Ahmad Mohammed FQ Al-Khanji
        Name: Ahmad Mohammed F Q Al-Khanji
        Title:    Chief of Legal and General Counsel
           
     

    Dated: February 2, 2022

     

     

     

     

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

      Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET.   The fireside chat will be webcast live and will be access

      5/27/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports 2025 First Quarter Financial Information¹

      Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is  

      5/23/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

      Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting.   The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Frédéric Cren, Chief Executive Officer and cofounder of Inventiva. Mr. Frederic Cren proceeded to the usual formalities of the opening of the meetin

      5/23/25 2:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:05 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:06 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/22/25 8:32:34 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

      Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

      12/16/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

      Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

      10/14/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the nomination of Andre Turenne as Director

      Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre

      3/28/24 3:00:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Inventiva with a new price target

      TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

      2/21/25 8:15:44 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Inventiva with a new price target

      UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

      11/12/24 7:43:33 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Inventiva with a new price target

      Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

      10/27/23 7:43:43 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 9:00:40 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 8:54:43 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      7/19/24 4:30:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    Financials

    Live finance-specific insights

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports its 2024 full year results and provides a business update

      Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

      3/26/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

      Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

      3/19/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care